<DOC>
	<DOCNO>NCT01353937</DOCNO>
	<brief_summary>Diabetic foot ulcer , complication diabetes lead 80.000 low limb amputation annually US , significant burden health system , cost billion dollar annually . Here , propose novel combination two drug ( Mozobil® Regranex®Gel ) mobilize specific sub-type stem cell ( endothelial progenitor cell ) bone marrow traffic toward wound , increase blood supply subsequently improve wound heal . Because use human body 's resource regenerate target correct underlie pathophysiology , believe novel therapy yield great promise treatment diabetic foot ulcer .</brief_summary>
	<brief_title>Endogenous Progenitors Cell Therapy Diabetic Foot Ulcers</brief_title>
	<detailed_description>Because diabetes impairs wound heal alter fibroblast function , promote chronic infection diminishes blood supply skin , lifetime risk person diabetes develop diabetic foot ulcer ( DFU ) high 25 % . Current strategy focus independently fibroblast dysfunction ( growth factor PDGF/Regranex® Gel ) , chronic infection ( debridement , antibacterial dressing ) blood supply ( VAC® ) . This project different project propose combine two drug dual approach first improve fibroblast function use PDGF/Regranex® Gel second induce neovascularization DFU recruiting progenitor cell wound combination therapy subcutaneous AMD3100 ( Plerixafor/Mozobil® ) topical PDGF/Regranex® Gel . By contrast novel stem cell therapy cell extract , process ex vivo engraft wound ( exogenous stem cell therapy ) , propose keep stem cell vivo ( endogenous stem cell therapy ) . Specifically , first aim study launch prospective evaluator-blind pilot phase I/II safety efficacy study evaluate clinical effect AMD3100 ( Plerixafor/Mozobil® ) treatment topical PDGF/Regranex® Gel compare historical control ( standard care PDGF ) . AMD3100 ( 240 µg/kg SC ) administer daily 2 week . Our primary endpoint measure percentage change area wind 4 week ( surrogate endpoint ) . In second aim , measure effect AMD3100 treatment PDGF use quality-of-life index dedicate DFU ( DFS-SF ) . Because address underlying physiopathology dual approach , avoid need ex vivo process drug FDA approve , believe novel therapy yield great promise treatment DFUs .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>1 . Insulindependant type 2 diabetic patient 2 . Age 35 60 yearsold 3 . HbA1C 6 12 % 4 . Fullthickness diabetic neuropathic foot ulcer 5 . ≥ 2 week duration 6 . Following standard care débridement , ulcer size must 1 6 cm2 7 . Adequate perfusion , define either transcutaneous oxygen measurement dorsum foot &gt; 30 mmHg ankle brachial index 0.7 &lt; ABI &lt; 1.2 , well toe pressure &gt; 30 mmHg . 1 . Clinical infection study ulcer site ( bacterial fungal ) 2 . Clinically significant lowerextremity ischemia ( define ankle/brachial index &lt; 0.65 ) 3 . Active Charcot 's foot determine clinical radiographic examination 4 . Ulcer nondiabetic pathophysiology ( e.g. , rheumatoid , radiationrelated , vasculitisrelated ulcer , especially venous stasis ulcer ) 5 . Significant medical condition would impair wound heal also exclude study . These condition include liver disease , aplastic anemia , scleroderma malignancy , treatment immunosuppressive agent steroid , myocardial infarct , stroke , major surgery within 6 month study , usage tobacco 6 . Subjects cancerous precancerous lesion area treat 7 . Body weight &gt; 160 kg ( Plerixafor 's pharmacokinetic limitation ) 8 . Severe renal dysfunction ( creatinine clearance &lt; 50 ml/min ) 9 . Severe nonproliferative proliferative diabetic retinopathy 10 . Capillary blood glucose &gt; 350</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>wound healing</keyword>
</DOC>